A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

BACKGROUND: Synergistic cytotoxicity with high-dose statins and erlotinib has been demonstrated in preclinical models across a number of tumour types. In this phase I study, we evaluated the safety and potential anti-tumour activity of escalating doses of rosuvastatin in combination with the standar...

Descripción completa

Detalles Bibliográficos
Autores principales: Goss, Glenwood D., Jonker, Derek J., Laurie, Scott A., Weberpals, Johanne I., Oza, Amit M., Spaans, Johanna N., la Porte, Charles, Dimitroulakos, Jim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815068/
https://www.ncbi.nlm.nih.gov/pubmed/27036206
http://dx.doi.org/10.1186/s12967-016-0836-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815068/
https://www.ncbi.nlm.nih.gov/pubmed/27036206
http://dx.doi.org/10.1186/s12967-016-0836-6

Ejemplares similares